CORC

在结果中检索

CORC

浏览/检索结果: 共34条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC 期刊论文
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 卷号: 140, 页码: 510-527
作者:  Chen, Lingfeng;  Fu, Weitao;  Feng, Chen;  Qu, Rong;  Tong, Linjiang
收藏  |  浏览/下载：57/0  |  提交时间：2019/01/08
Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1 期刊论文
ACTA PHARMACEUTICA SINICA B, 2017, 卷号: 7, 期号: 6, 页码: 657-664
作者:  Cheng, Xuewei;  Lv, Xia;  Qu, Hengyan;  Li, Dandan;  Hu, Mengmeng
收藏  |  浏览/下载：28/0  |  提交时间：2019/06/20
Facile Synthesis of Novel Perfluorocarbon-Modulated 4-Anilinoquinazoline Analogues 期刊论文
CHINESE JOURNAL OF CHEMISTRY, 2017, 卷号: 35, 期号: 11, 页码: 1693-1700
作者:  Shi, Huiping;  Lai, Bonan;  Chen, Shizhen;  Zhou, Xin;  Nie, Jing
收藏  |  浏览/下载：66/0  |  提交时间：2018/11/05
Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors 期刊论文
SCIENTIFIC REPORTS, 2017, 卷号: 7
作者:  Hao, Yongjia;  Lyu, Jiankun;  Qu, Rong;  Sun, Deheng;  Zhao, Zhenjiang
收藏  |  浏览/下载：34/0  |  提交时间：2019/01/08
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study 期刊论文
BMC CANCER, 2017, 卷号: 17
作者:  Yang, Zhen-Zhou;  Li, Meng-Xia;  He, Hao;  Ruan, Zhi-Hua;  Zhu, Yu-Xi
收藏  |  浏览/下载：2/0  |  提交时间：2019/12/04
Meta-analysis of efficacy and adverse events of erlotinib-based targeted therapies for advanced/metastatic non-small cell lung cancer 期刊论文
ONCOTARGET, 2017, 卷号: 8, 期号: 49
作者:  Li, Fei;  Zhang, Shu-Hua;  Pang, Li-Min
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11
作者:  Goss, G.
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 会议论文
作者:  Li, W.;  Gadgeel, S. M.;  Soria, J. C.;  Felip, E.;  Cobo, M.
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 期刊论文
EUROPEAN JOURNAL OF CANCER, 2017, 卷号: 72
作者:  Goss, G.;  Cobo, M.;  Lu, S.;  Soria, J. C.;  Syrigos, K.
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers 会议论文
作者:  Isla, Dolores;  Min, Young Joo;  Ardizzoni, Andrea;  Gadgeel, Shirish;  Dupuis, Nicholas
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05

©版权所有 ©2017 CSpace - Powered by CSpace